Medivation: When Earnings are an Afterthought

Everyone who is everyone wants to buy Medivation ( MDVN ). Sanofi ( SNY ) has bid more than $9 billion for the biotech company , while Medivation is often presented as a cure for what ails Gilead Sciences ( GILD ). Pfizer ( PFE ), and Amgen ( AMGN ) have also been mentioned as potential suitors . In fact, many think its not a question of when Medivation will be bought but for how much. But, hey, analysts are analysts, and they still have to put out their earnings forecasts, even if they justify it as "in case the sale falls through," as Stifel's Thomas Shrader and team do in a note released yesterday: